POLYTECHNIC COLLEGE OF DAVAO DEL SUR, INC.

MacArthur Highway,Brgy.Kiagot,Digos City, Davao del Sur, Philippines 8002

DRUG STUDY
Name of Patient: Attending Physician:
_______________________________________________
Age: Sex: Civil Status: Diagnosis: ____________________________________________
Occupation:
Religion:
Address: Chief Complaint: _______________________________________
Ward: Room No.: Bed No.: Date of Admission: ___________________________________________
DATE/ BRAND ACTION INDICATION ROUTE/ DRUG ADVERSE PRECAUTION NURSING
NAME INTERACTION EFFECT CONTRADICT RESPONSIBILITIES
TIME DOSAGE/ ION
ORDERED
TIME
INTERVAL

Inhibits bacterial Black Box Extended- Drug-drug. CNS: Contraindicated  Tell patient not
DNA synthesis, Warning Use in and Aluminum seizures, in patients to divide tablets
mainly by patients with immediate- hydroxide, confusion, sensitive to fluo but to take them
Generic blocking DNA acute sinusitis, release oral aluminum- headache, roquinolones. whole, with food
Name: gyrase; acute PO forms magnesium rest- or shortly after a
bactericidal exacerbations of aren't hydroxide, lessness. Gl: Alert: Serious
Cipro meal.
chronic interchangeab calcium pseudomem and occasionally
 Advise patient to
bronchitis, and le. Obtain carbonate, branous fatal hy-
report to
acute specimen for didanosine colitis, persensitivity
Classificati prescriber ad-
uncomplicated culture and (chewable tablets, diarrhea, reactions, some
on: verse reactions
UTI isn't sensitivity buffered tablets, nausea, after first dose,
and signs of
recommended tests before or pediatric vomiting. have been
hypocalcemia,
because of risk of giving first powder for oral GU: crystal- reported.
which include
serious ad- verse dose. Begin solution), luria, Emergency
paresthesia,
effects. Use in therapy while magnesium interstitial treatment for
muscle
these patients only awaiting hydroxide, nephritis. anaphylaxis may weakness,
when there are no results. products Hematologi be necessary. muscle
other treatment containing zinc: c: Immediately cramping, and
options.  To May decrease leukopenia, discontinue drug muscle spasm.
avoid ciprofloxacin neutropenia, at first  Advise patient to
 Complicat decrea absorption and thrombocyt appearance of immediately
ed intra- sing effects. Give openia, rash, jaundice, or report signs or
abdominal the ciprofloxacin 2 eosinophilia other signs and symptoms of GI
infection effect hours before or 6 . symptoms of hy bleeding, such
 Complicat s of hours after these Musculoske persensitivity. as black or tarry
ed intra- ciprof drugs. letal: tendon stool, bright red
abdominal loxaci Cyclosporine: rup ture. Alert: Cases of
blood in vomit,
infection n, May increase risk Skin: rash, severe
dark or bright
 Severe or give for cy- closporine SJS, toxic hepatotoxicity,
red blood mixed
complicate at toxicity. Monitor epidermal in- cluding fatal
with stool, and
d UTI; least 2 cyclosporine necrol ysis. events, have been
abdominal
mild to hours level. Drugs Other: reported. Acute
cramps.
bone or before primarily hypersensiti liver injury can
joint or metabolized vity be rapid and is
infection; ciprof CYP1A2 reactions. fre- quently
mild to loxaci (caffeine, associated with
moderate n 329 clozapine, hypersensitivity.
respiratory 6 methylxanthines, If signs and
infection; hours olan- zapine, symptoms of
mild to after theophylline, hepatitis occur,
moderate certai tizanidine, dis- continue
skin or n ropinirole, immediately.
skin- drugs zolpidem): May Alert: Patients
structure and increase plasma receiving
infection; vitami concentra- tions systemic drug
infectious ns. of coadministered have an increased
diarrhea; Food drug, leading to risk of
typhoid doesn' clin- ically hyperglycemia
fever t significant and
 Complicat affect adverse reactions hypoglycemia,
ed UTI or absor of coad- which can result
pyeloneph ption ministered drug. in coma.
ritis but Monitor patient Hypoglycemia
may for adverse
 pneumonia delay reactions. has been reported
peak more fre quently
levels in the elderly and
 Caffei in those with dia-
ne betes. Alert:
shoul Drug may
d be increase risk of
avoid aortic dissection
ed or rupture when
during used systemi-
ther cally. Avoid use
apy in patients with
with known aor- tic
this aneurysm or who
drug are at risk for
becau aortic aneurysm,
se of including those
potent with peripheral
ial for atherosclerotic
increa vascular diseases,
sed HTN, or certain
caffei genetic
ne conditions
effect (Marfan
s. syndrome,
 Give Excretion: Ehlers-Danlos
drug syndrome), and
with elderly pa- tients.
plenty Drug should only
of be used in these
fluids patients if no
to other treatment
reduc options are
e risk available.
of
• Use cautiously
urine
in patients with
crysta
CNS disor ders,
ls.
such as severe
  Don't cerebral
crush arteriosclerosis or
or seizure disorders,
split and in those at
exten risk for seizures.
ded- Drug may cause
releas CNS stimulation.
e Black Box
tablets Warning Drug is
 Shake associated with
oral risk of tendinitis
suspe and tendon
nsion rupture,
vigoro especially in
usly patients older
each than age 60 and
time those with heart,
before kidney, or lung
use transplants. Drag
for may exacerbate
appro muscle weakness
ximat in patients with
ely 15 myasthe nia
secon gravis. Avoid use
ds; of
don't fluoroquinolones
give in patients with a
throug known history of
h myasthenia Art
feedin Oral or parenteral
g fluoroquinolones
tube.. gravis. may
increase the risk
of peripheral
Absorption: neuropa- By of
the arms or lege
Symptoms can oc
cur anytime
during treatment
and can last for to
years or be
permanent. Stop
drug immediately
if patient
develops
symptoms and
switch to a
nonfluoroquinolo
ne antibac- terial
drug unless the
benefits of
continued
treatment
outweigh the
risks.
Black Box
Warning
Fluoroquinolones
have been
associated with
disabling and
potentially h
irreversible
serious adverse
reactions that
have occurred
together,
including
tendinitis and
tendon rupture,
peripheral
neuropathy, and
CNS effects.
Drug is
associated with
in- creased risk of
serious adverse
CNS reactions
(seizures, toxic
psychoses,
increased ICP,
pseudotumor
cerebri, tremors,
restlessness,
anxiety, light-
headedness,
confusion, hallu-
cinations,
paranoia,
depression,
nightmares,
insomnia,
disturbances in
attention,
disorien- tation,
agitation,
memory
impairment,
delir- ium and,
rarely, suicidal
thoughts or acts).
If any of these
serious adverse
reactions occur,
discontinue drug
immediately.
Black Box
Warning Reserve
drug for use in
patients who
have no
alternative
treatment op-
tions for acute
exacerbation of
 chronic bron-
chitis and acute
sinusitis.
Drug may cause
CDAD ranging in
severity from
mild diarrhea to
fatal colitis and
possi- bly
occurring apy
ends. Drug may
need to be
discontinued
more than 2
months after ther-
if CDAD
develops during
therapy.
Dialyzable drug:
Less than 10%.

Student Name: DENNIELLE JAY T. VICENTE Year & Sec: BSN 2C Group No: 1-B Rating:__________
References:___________________________________________________________________________________________________________
Criteria: Promptness (15%) Objectives of Care (10%),,
Format/Neatness (15%) Nursing Action (30%),
Assessment (15%) Evaluation (10%)
Nursing Diagnosis (15%)
Clinical Instructor:___MA. LERHIE PARADILLO, RN______________